Mitral Valve Regurgitation Clinical Trial
Official title:
Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY)
This is a prospective, multicenter, open-label, randomized trial comparing mitral valve (MV) transcatheter edge-to-edge repair (TEER) to surgical repair (1:1 ratio) in patients with primary, degenerative mitral regurgitation (MR). The trial will be conducted in the U.S., Canada, Germany and the United Kingdom, and is designed as a strategy trial. Thus, all devices legally marketed for TEER of primary degenerative MR in a particular country are eligible to be used in this trial.
The primary aim of this study is to evaluate the long-term effectiveness and safety of MV TEER compared with surgical repair in patients with primary, degenerative MR. The secondary aim is to analyze the relationship between the adequacy of MR correction at one-year post intervention and longer-term clinical outcomes (death, heart failure hospitalizations/urgent care visits, valve re-interventions, and quality of life). The tertiary aim of this trial is to evaluate a range of patient-centered outcomes (quality of life, functional status, and discharge location) of transcatheter edge-to-edge MV repair compared with MV surgical repair in patients with primary, degenerative mitral regurgitation. The patient population for this trial consists of adult patients with severe, primary degenerative MR for whom the local heart team has verified that an indication for MV intervention is present and for whom both transcatheter edge-to-edge and surgical repair strategies are anatomically feasible. Because the use of the commercial edge-to-edge mitral repair device in the U.S. is approved only in patients considered to be at prohibitive risk of MV surgery by a heart team, use of such devices in this trial is considered investigational by the FDA. As such, this trial will be conducted under an Investigational Device Exemption (IDE ). Outcomes will be measured from randomization over a period of 5 years post intervention. The estimated enrollment period is 36 months, and all patients will be followed from randomization for up to 10 years post intervention for particular endpoints. Long-term follow-up will include leveraging administrative datasets linked to clinical trial data. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02520310 -
AVJ-514 Japan Trial
|
N/A | |
Not yet recruiting |
NCT06465745 -
AltaValve Pivotal Trial
|
N/A | |
Completed |
NCT02355418 -
The Role of Myocardial Fibrosis in Degenerative Mitral Regurgitation
|
||
Recruiting |
NCT04577248 -
The Prospecive OBSERVational Munich Interventional MITRAl-Valve Registry
|
||
Recruiting |
NCT03242642 -
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
|
N/A | |
Recruiting |
NCT02961647 -
Hemodynamic Stress Test in Severe Mitral Regurgitation (HEMI)
|
N/A | |
Active, not recruiting |
NCT02302872 -
Treatment of Heart Failure and Associated Functional Mitral Valve Regurgitation
|
N/A | |
Completed |
NCT01777815 -
Safety and Performance Study of the NeoChord Device
|
N/A | |
Withdrawn |
NCT00428103 -
Effects of Mitral Valve Repair With the Geoform Ring on Cardiomyopathy
|
N/A | |
Completed |
NCT04351984 -
Transcatheter Mitral Valvuloplasty Pilot Study
|
||
Withdrawn |
NCT02722551 -
CardiAQ-Edwards™ Transcatheter Mitral Valve Replacement (TMVR) Study
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02321514 -
Expanded Clinical Study of the Tendyne Mitral Valve System
|
N/A | |
Recruiting |
NCT02245763 -
STS/ACC TVT Registry Mitral Module
|
||
Active, not recruiting |
NCT01740583 -
Mitralign Percutaneous Annuloplasty System for Chronic Functional Mitral Valve Regurgitation
|
N/A | |
Completed |
NCT00800046 -
A Study of Percutaneous Repair of Functional Mitral Regurgitation Using the Ancora Heart, Inc. AccuCinch® Ventricular Repair System - The CINCH-2 Study
|
N/A | |
Completed |
NCT00415701 -
Effect of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery
|
Phase 4 | |
Recruiting |
NCT03908983 -
OPtimisation of Surgical Repair for Treating Insufficiency of the MItral Valve - Safety and Effectiveness Evaluation
|
N/A | |
Active, not recruiting |
NCT04818502 -
Real World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation
|
||
Terminated |
NCT03285724 -
Safety and Performance Study of the Harpoon Mitral Valve Repair System
|
N/A | |
Recruiting |
NCT04195984 -
Mi-thos® Transcatheter Mitral Valve Replacement Study
|
N/A |